Daily closing price · 250 sessions
Quantitative price outlook based on available market signals. Not financial advice.
Indicators calculated from the stored daily price history.
A verified, data-driven analysis will be generated here from price action, technical indicators, fundamentals, earnings and market context.
Dedicated research sections for 2026, 2030, 2035, 2040 and 2050. Numerical targets will appear only after the long-horizon model is validated.
Research inputs: earnings, revenue growth, valuation, technical regime, volatility, sector context and market conditions.
Read 2026 research →Research inputs: earnings, revenue growth, valuation, technical regime, volatility, sector context and market conditions.
Read 2030 research →Research inputs: earnings, revenue growth, valuation, technical regime, volatility, sector context and market conditions.
Read 2035 research →Research inputs: earnings, revenue growth, valuation, technical regime, volatility, sector context and market conditions.
Read 2040 research →Research inputs: earnings, revenue growth, valuation, technical regime, volatility, sector context and market conditions.
Read 2050 research →Historical outcomes are shown only after a prediction has matured and been evaluated.
Absolute percentage error: 5.63%
Absolute percentage error: 6.21%
Only stories explicitly associated with this stock are shown.
Wall Street declined on Tuesday as rising Treasury yields and debt concerns weighed on investor sentiment, particularly affecting discretionary and utilities stocks. The Dow fell 0.6%, Nasdaq dropped 0.8%, and S&P 500 lost 0.5%. Energy stocks bucked the trend, gaining 2.3% as oil prices surged due to Saudi supply disruptions. Markets are pricing in a 94.5% likelihood of a Fed rate hike on Wednesday.
Exxon Mobil (XOM) rose 2.42% to $169.08, outperforming the S&P 500's 0.45% decline. The company is expected to report Q3 EPS of $3.78 (up 101% YoY) and revenue of $104.88 billion (up 23% YoY). With a Zacks Rank #3 (Hold) rating and a Forward P/E of 13.84 (above industry average of 8.9), the stock trades at a premium valuation despite strong earnings growth expectations.
Common questions about price, predictions, long-term forecasts, technicals and research methodology.
XOM is currently shown at $163.32 in the latest stored market quote. The page is refreshed from the connected market-data pipeline.
US Market AI currently shows quantitative forecasts for 24H, 7D, 30D and 90D using the stored market signals. The forecasts are estimates and not guarantees.
The 2026 long-term forecast section is included as a research framework. A numerical 2026 target is shown only after a dedicated long-horizon model has produced and validated it; the current 24H–90D model is not presented as a 2026 target.
The 2030 section tracks the inputs that a validated long-horizon model should use, including company growth, valuation, earnings, market regime and sector conditions. No unsupported price target is displayed.
The 2035, 2040 and 2050 sections are reserved for long-term model outputs. US Market AI does not invent numerical targets when validated long-horizon data is unavailable.
The page can display RSI, MACD, SMA 50, SMA 200, EMA 20, ATR, ADX, volatility, Bollinger levels, stochastic, support and resistance from stored daily price history.
Fundamental data is not currently populated for this stock, so the page does not estimate or fabricate missing values.
The latest ticker-linked news appears in the Market News section of this page. Stories are shown with source, publication date and sentiment when available.
Only predictions that have matured are evaluated. Recent evaluated outcomes are shown in the model-validation section; accuracy should be interpreted using the full mature sample rather than a single result.
No. US Market AI provides research and model estimates for informational purposes. Forecasts can be wrong and should not be treated as personalized financial advice.
US Market AI combines quantitative signals and verified market data to support research. Forecasts are estimates, can be wrong, and are not financial advice.